All results

3 results for randomized double blind placebo controlled study assess efficacy safety and

• PVT-2201-301

  This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with…

  Ages

  18 Years - 75 Years

  Sexes

  All

• ATYR

  This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…

  Ages

  18 Years - 75 Years

  Sexes

  All

• Efficacy and Safety of AMG 570 in Subjects With Active SLE

  The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…

  Ages

  18 Years - 75 Years

  Sexes

  All